Improvement of sustained virologic response (SVR) in the treatment of chronic hepatitis c genotype 1 with PEG-IFNalpha-2b by ribavirin dose adjustments: evidence obtained from the…
S Mauss, E Zehnter, D Hüppe, M Manns, G Teuber, D Tarek, T Witthöft, B Möller, N Dikopoulos, J Brack, K Dach, M Bilzer, G Tossing · Zeitschrift für Gastroenterologie · 2010 · Heft 01
Bibliografische Angaben
Zusammenfassung
Aims: Two peginterferon (weight-based PEG-IFNα-2b and fixed-dose PEG-IFNα-2a) and ribavirin (RBV) regimens approved for HCV treatment were recently compared in the IDEAL study. While overall SVR rates of pts infected with G 1 were similar with both regimens, a 10% difference was observed for pts weighing 75–85kg. The latter were treated either with PEG-IFNα-2b (1.5µg/kg/wk)+1000mg RBV/d or PEG-IFNα-2a (180µg/wk)+1200mg RBV/d suggesting RBV underdosage in the PEG2b regimen. We re-evaluated SVR rates of G 1 pts treated in the German Peg-IFNα-2b/ribavirin observational cohort study within different body weight clas…
